Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Immunol. 2010 Mar;134(3):289-95. doi: 10.1016/j.clim.2009.11.001. Epub 2009 Nov 25.

The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo.

Author information

  • 1The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. tyedin@wehi.edu.au

Abstract

Effective treatment of celiac disease is an unmet medical need. A glutenase that destroys immunogenic gluten peptides may be clinically valuable. Twenty patients with celiac disease were randomly assigned to ingest a large gluten meal (16 g daily for 3 days) pre-treated with ALV003, a mixture of highly specific glutenases (n=10), or pre-treated with placebo (n=10). Peripheral blood T-cell IFN-gamma ELISpot responses to gliadin and an immunogenic 33mer and symptoms were assessed. While baseline IFN-gamma ELISpot responses to gliadin and the 33mer were negative in all patients, a significant ELISpot response to gliadin or the 33mer was observed in 6 of 10 patients consuming placebo-treated gluten and 0 of 10 consuming ALV003 pre-treated gluten (p=0.011). Symptoms typically associated with gluten ingestion occurred in both groups and were not significantly reduced by ALV003 pre-treatment. ALV003 pre-treatment can abolish immune responses induced by gluten in patients with celiac disease.

2009 Elsevier Inc. All rights reserved.

PMID:
19942485
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk